THE POWER OF PLUS
Where Partnership Intersects with Possibilities
Where Partnership Intersects with Possibilities
The Power of Plus

At Takeda, we’re looking for partners who believe our global reach, deep scientific expertise and clinical excellence can help them bring their vision to market.

We’ve been putting patients first for more than 235 years. Our centuries-old values of integrity, fairness, honesty and perseverance guide how we operate and how we work with partners.

If better health and a brighter future for people everywhere is our why, partnering is our how. We believe deeply in the power of Takeda plus our partners.
Patient-centric, partner-focused

Our outside-in mindset is focused on identifying innovations both outside and within our walls. We think differently – and creatively – about how we work with our partners and build on our combined strengths across all stages of discovery, development and commercialization. The Power of Plus means creatively combining our expertise with yours to improve patient health.
Leveraging what we do best – together

At Takeda, we deeply value your company’s expertise, skills and unique culture, and will help you leverage the benefits of teaming with Takeda: a flexible, people-oriented company; an ecosystem of academic institutions, nonprofit organizations, venture capital firms and biopharmaceutical peers; and a highly motivated alliance team with commercial expertise and a track record of success across the entire product lifecycle.
Unique approach – differentiated results

Takeda is open for business – open to exploring new and different ways of partnering with you. We’ve structured our partnering organization to support creative collaborations tailored to your unique needs, ranging from innovative deal structures to novel implementation models and beyond. Count on our alliance team to operate nimbly and follow through on our commitments.
Sharing success in the true spirit of partnership

How we operate and work with partners is guided by Takeda’s core values, forged over 235-plus years. They are the inspiration for our spirit of collaboration and the foundation of how we pursue our mission “to strive towards Better Health and a Brighter Future for people worldwide through leading innovation in medicine.”
MEET YOUR TEAM

Dan Curran, MD
Head, Center for External Innovation
daniel.curran@takeda.com

Marcello Agosti
Head, Global Commercial and Global Business Development
marcello.agosti@takeda.com

Ken Araki
Corporate Development
ken.araki@takeda.com

Tauhid Ali, PhD
R&D “TAK-celerator” Externalization Initiatives
tauhid.ali@takeda.com

John Bathery
US Business Development
john.bathery@takeda.com

Mike Broxson
R&D Business Development
mike.broxson@takeda.com

Dan Gandor
US Digital Accelerator
daniel.gandor@takeda.com
The **pluses** of partnering with Takeda

+ Faster path through the product lifecycle
+ Creative, customized collaboration
+ Dedicated alliance management team and resources
+ Respect for your independence and decision-making
+ Clear two-way accountability
Case Studies
Crescendo Biologics + Takeda
Therapies for cancer indications with high unmet medical needs, including tumor targeting drug conjugates and immuno-oncology therapeutics

OUTSIDE-IN INNOVATION

Next generation of unique, small and customizable Humabody®-based therapeutics.

CRESCEndo BIOLOGICS
Proprietary Humabody®-based therapeutics

TAKEDA
Oncology expertise, including antibody drug conjugates

DEAL HIGHLIGHT
Developing the next generation of unique, small and customizable Humabody®-based therapeutics using highly modular and targeted therapies
Ultragenyx + Takeda

Expedite early-stage drug discovery of innovative new therapies

OUTSIDE-IN INNOVATION
Development of therapies for patients with rare diseases that have few or no treatment options.

ULTRAGENYX
Strong patient-centric development and regulatory capabilities in rare disease space

TAKEDA
Early pipeline of therapies across a number of rare genetic diseases

DEAL HIGHLIGHT
Five-year collaboration enabling development of therapies for patients with rare diseases
7 of the 10 leading causes of disability worldwide are CNS disorders.

OUTSIDE-IN INNOVATION

Novel therapeutics for neurological and psychiatric disorders.

CEREVANCE
The company will use new technology created in the Howard Hughes Medical Institute laboratory at Rockefeller University.

TAKEDA
25-person neuroscience research team, fully equipped laboratory space, licenses to preclinical and clinical stage drug program portfolio.

DEAL HIGHLIGHT
An entrepreneurial research setting to rapidly advance new technology and therapeutic treatments for brain diseases.
Bridge Medicines + Takeda
Accelerated path to innovative therapies to treat disease

OUTSIDE-IN INNOVATION
Advance promising early technologies in major academic institutions through human proof of concept.

BRIDGE MEDICINES
Financial, operational and managerial support to move from proof-of-concept study to in-human clinical trial. Formed by Tri-Institutional Therapeutics Discovery Institute (TRI-I TDI) and Takeda.

TAKEDA
Industry expertise across the lifecycle

DEAL HIGHLIGHT
Projects managed in a VC setting; transformational model strives to shave years off normal process
Seeking the best science, technologies and assets to collaborate on improving patient health

**Oncology**
- Multiple myeloma
- Other hematological malignancies
- Solid tumors - GI, GU, lung and breast cancers
- Novel targeted payload approaches - ADCs, PDCs, CD3 engagers, etc.
- Novel immuno-oncology approaches
- Novel approaches targeting protein homeostasis

**Gastroenterology**
- Crohn’s disease
- Ulcerative colitis
- GI Motility disorders
- NASH
- Celiac disease
- Microbiome approaches
Central Nervous System

+ Treatment Resistant Depression (TRD)
+ Cognitive impairment associated with schizophrenia (CIAS) and/or negative symptoms
+ Neurodegenerative disorders and associated dementias

Research & Technologies

+ Immunoprofiling
+ Gut-targeted drug-delivery
+ ‘Humanized’ preclinical models for immuno-modulation

Seeking the best science, technologies and assets to collaborate on improving patient health